Trial Profile
Efficacy and safety of Yokukansan for treatment-resistant shizophrenia: a randomised, double-blind, placebo-controlled multicentre trial.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs TJ 54 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 09 Feb 2011 New trial record